Upstate Active Clinical Trials
Study Title:
ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)What is the purpose of the study? (in Layman's terms, please describe the study)
Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)Upstate Institutional Review Board (IRB) Number:
1762877Study/Protocol ID:
ACNS1833Study Phase:
IIIPatient Age Group:
Adults and ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
Patients must be ≥ 2 years and ≤ 21 years at the time of enrollment.What is involved if I participate?
- How long is the study?
approx 2 years - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
surgery, blood draws, lumbar puncture, imaging
Where will the study take place?
SUNY Upstate Medical UniversityOther Information:
N/AWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]